Skip to main content

REVIEW article

Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1387157
This article is part of the Research Topic Drug Discovery in Cancer Research: Success Stories and Open Challenges View all 15 articles

Wedelolactone as pharmacological agent: focus on anticancer potential

Provisionally accepted
Xiaomeng Li Xiaomeng Li 1*Azhar Rasul Azhar Rasul 2Ayesha Sarfraz Ayesha Sarfraz 2*Mudassir Hassan Mudassir Hassan 2*
  • 1 KingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, Guizhou Province, China
  • 2 Government College University, Faisalabad, Faisalabad, Punjab, Pakistan

The final, formatted version of the article will be published soon.

    Natural products research has sparked the development of pharmacologically active compounds along with various blockbuster drugs derived from plants. These nature’s gifts for mankind have served as robust resources for potential drug candidates because of their powerful pleiotropic effects on molecular targets. This study aims to review such a nature’s gift, wedelolactone. Wedelolactone is a bioactive constituent of Wedelia calandulaceae L. e, Eclipta alba, and Coldenia procumbens. Currently, wedelolactone has emerged as a novel anti-cancer molecule. Wedelolactone possesses various pharmacological properties but this review is designed to present a comprehensive overview of its anti-cancer potential. Wedelolactone combats cancer by targeting metabolic reprogramming, and dysregulated signaling networks and by prompting apoptosis. Yet further research is needed in a more intensified fashion to develop a novel and active compound wedelolactone as the lead into an urgently needed efficacious anti-cancer drug.

    Keywords: Wedelolactone, anticancer, Natural Products, Metabolism, molecular targets

    Received: 16 Feb 2024; Accepted: 15 Jul 2024.

    Copyright: © 2024 Li, Rasul, Sarfraz and Hassan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xiaomeng Li, KingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, Guizhou Province, China
    Ayesha Sarfraz, Government College University, Faisalabad, Faisalabad, 38000, Punjab, Pakistan
    Mudassir Hassan, Government College University, Faisalabad, Faisalabad, 38000, Punjab, Pakistan

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.